Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Of India To Close Three Southeast Asia Plants

This article was originally published in PharmAsia News

Executive Summary

India's Ranbaxy Laboratories plans to close three of its Southeast Asia plants, one each in China, Malaysia and Vietnam. The strategy is intended to save the firm about $30 million, according to sources, but Ranbaxy would not comment. The company is said to be seeking buyers for the plants as the firm's first move to sell assets in the wake of its acquisition by Japan's Daiichi Sankyo. The Ranbaxy Guangzhou China plant was the first Sino-Indian partnership across business sectors and the first plant in China to get good manufacturing practices approval. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts